Atara Biotherapeutics’ layoffs could leave the biotech with around 80 employees. The cuts follow news that the FDA rejected Ebvallo, a T cell therapy approved in Europe for a transplant-related blood ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is rated as a Buy.

Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...

LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

Atara Biotherapeutics said on Tuesday the U.S. health regulator had placed a clinical hold on its trials for cancer cell ...

The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...

Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC ...

Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...

H.C. Wainwright maintained its Neutral stance on Atara Biotherapeutics stock (NASDAQ:ATRA), following the company's announcement of a significant workforce reduction. According to InvestingPro data, ...

On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) active Investigational New Drug (IND) applications. These INDs include the ...

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219 ...